Antibody therapies

Antibody therapies has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 22, 2026: “A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA”.

Intervention

1 paper studies it2 findingsUpdated

See all 1 papers on antibody therapies

What did studies of antibody therapies find?

2

Studies of antibody therapies measured 2 outcomes: cognitive decline and amyloid plaque.

Cognitive decline

downin humans1

1 study
  1. Antibody therapies decrease cognitive decline in people with Alzheimer's disease who are mildly impaired.

    Reviewin people with Alzheimer's disease who are mildly impaired

Amyloid plaque

downin humans1

1 study
  1. Antibody therapies decrease amyloid plaque in people with Alzheimer's disease who are mildly impaired.

    Reviewin people with Alzheimer's disease who are mildly impairedbrain

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months